HIV-1 remains an incurable infection due to the persistence of latent reservoirs and the limitations of antiretroviral therapy (ART), which requires lifelong adherence. Chimeric antigen receptor (CAR)-T cell therapy offers a promising strategy to eliminate HIV-infected cells; however, current CAR-T approaches face challenges such as low antigen (Env) density on infected cells and limited T cell persistence. This project aims to develop a novel CAR-T therapy co-expressing a chimeric costimulatory receptor (CCR) targeting CD7, enhancing immune cell interactions and improving CAR-T cell function. The dual CAR\CCR-T cell system is designed to increase antigen engagement, promote T cell survival, and boost cytotoxicity, overcoming key barriers in HIV therapy. The efficacy of CAR\CCR-T cells will be evaluated in vitro, ex vivo using samples from people living with HIV, and in vivo in a humanized mouse model. This project will provide critical insights into CAR-T cell optimization and may pave the way for a functional HIV cure, with broader applications in other chronic infections and oncology.